February 2015
The stem cell research division of the Tisch MS Research Center of New York is pleased to announce the completed enrollment of 20 patients to participate in the phase I clinical trial investigating the safety and efficacy of autologous, mesenchymal stem cell-derived neural progenitors (MSC-NPs) for the treatment of multiple sclerosis. We are no longer recruiting for this study. Interim results of this clinical trial will be presented at upcoming scientific conferences and simultaneously announced on our website. All questions regarding participation in any future clinical trials should be discussed with your neurologist.
MS Views and News supports the Tisch MS Stem Cell Research Center
If you would like to contribute to these research efforts, please donate here
In the notes section, please mention for Stem Cell research
- Finding the Cause of MS
- Understanding the Mechanisms of Disease Progression
- Developing Repair Strategies in MS
- Conducting Translational Research
- Biomarker Research
.